Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II).
Yuan Tang, Hao-Yue Li, Li-Chun Wei, Ning Li, Wen-Jue Zhang, Yu-Fei Lu, Fei-Yan Deng, Tong-Zhen Xu, Jia-Cheng Shuai, Zi-Fa Lei, Xian-Yu Meng, Shu-Nan Qi, Yong-Wen Song, Wen-Wen Zhang, Hao Jing, Gong Li, Shi-Xin Liu, Ying-Jie Wang, Zheng Liu, Hui-Ying Ma, Ning-Yu Wang, Bo Chen, Shu-Lian Wang, Ye-Xiong Li, Li-Na Zhao, Jian-Qiang Tang, Zheng Jiang, Ying-Gang Chen, Hai-Tao Zhou, Chen Hu, Jing Jin
Med 6(11) 100807
摘要
摘要
BACKGROUND: The therapeutic efficacy and mode of combining immunotherapy with neoadjuvant chemoradiotherapy in proficient mismatch repair (pMMR)/microsatellite stable (MSS) locally advanced rectal cancer (LARC) remain uncertain. METHODS: In this multicenter, randomized, seamless phase 2/3 trial (ClinicalTrials.gov: NCT05484024), eligible participants were randomly assigned (1:1) to receive short-course radiotherapy (SCRT) (5 Gy × 5), followed by 4 cycles of capecitabine and oxaliplatin or 6 cycles of leucovorin, oxaliplatin, and fluorouracil, with (iTNT group) or without (total neoadjuvant therapy [TNT] group) 4 cycles of sintilimab. Following neoadjuvant therapy, participants underwent surgery or a watch-and-wait strategy based on clinical complete response. The primary endpoints were the complete response (CR) rate for phase 2 and the 3-year disease-free survival (DFS) rate for phase 3. FINDINGS: 218 patients were randomized to the iTNT group (n = 110) and the TNT group (n = 108). All patients completed SCRT, with 88.2% in the iTNT group and 93.5% in the TNT group completing 4 cycles of neoadjuvant treatment. The CR rate was significantly higher in the iTNT group (45.5% vs. 25.0%; p = 0.003). Grade 3-4 treatment-related adverse events were reported in 34.5% of the iTNT group and 19.4% of the TNT group (p = 0.012), with thrombocytopenia, diarrhea, leukopenia, and neutropenia being the most frequently observed. Grade 3-4 immune-related adverse events occurred in 5.5% of patients in the iTNT group. CONCLUSIONS: The addition of the PD-1 inhibitor sintilimab significantly enhances the CR rate compared to SCRT-based TNT, with favorable tolerability in patients with pMMR/MSS LARC. FUNDING: This work was funded by the National Natural Science Foundation of China (82473248) and the Shenzhen Medical Research Fund (C2301001).
KM 提取结果
0 个 Figure · 0 个 KM 面板